Gyre Therapeutics (GYRE) to Release Earnings on Tuesday

Key Points

• Gyre Therapeutics (NASDAQ:GYRE) is expected to announce its Q2 2025 earnings on August 12th, with anticipated earnings of $0.03 per share and revenue of $30.80 million.
• The company's previous earnings report indicated that Gyre achieved $0.03 EPS, matching consensus estimates, but revenue fell short at $22.06 million compared to an expected $28.40 million.
• Bank of America Corp DE increased its stake in Gyre Therapeutics by 40.4% recently, indicating growing institutional interest in the company.

Gyre Therapeutics (NASDAQ:GYRE - Get Free Report) is expected to be posting its Q2 2025 quarterly earnings results before the market opens on Tuesday, August 12th. Analysts expect Gyre Therapeutics to post earnings of $0.03 per share and revenue of $30.80 million for the quarter.

Gyre Therapeutics (NASDAQ:GYRE - Get Free Report) last posted its earnings results on Friday, May 9th. The company reported $0.03 EPS for the quarter, hitting analysts' consensus estimates of $0.03. Gyre Therapeutics had a return on equity of 9.73% and a net margin of 7.20%. The business had revenue of $22.06 million for the quarter, compared to analysts' expectations of $28.40 million.

Gyre Therapeutics Price Performance

Shares of GYRE traded down $0.01 during midday trading on Friday, reaching $7.19. 85,321 shares of the stock were exchanged, compared to its average volume of 78,832. The business's 50-day moving average price is $7.69 and its 200 day moving average price is $9.24. Gyre Therapeutics has a twelve month low of $6.11 and a twelve month high of $19.00. The company has a market capitalization of $674.12 million, a price-to-earnings ratio of 359.68 and a beta of 1.80.

Institutional Investors Weigh In On Gyre Therapeutics

A hedge fund recently raised its stake in Gyre Therapeutics stock. Bank of America Corp DE raised its holdings in Gyre Therapeutics, Inc. (NASDAQ:GYRE - Free Report) by 40.4% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 6,937 shares of the company's stock after acquiring an additional 1,996 shares during the period. Bank of America Corp DE's holdings in Gyre Therapeutics were worth $84,000 at the end of the most recent reporting period. 23.99% of the stock is owned by institutional investors and hedge funds.

About Gyre Therapeutics

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.